Zhaoke Ophthalmology Strikes Exclusive Distribution Deal for CsA Ophthalmic Gel in Indonesia
Key Highlights
- Distribution Deal Signed: Zhaoke Ophthalmology Limited has entered an exclusive distribution and supply agreement with PT. Erlangga Edi Laboratories (PT. Erela), a leading Indonesian pharmaceutical company.
- Product Involved: The agreement covers CsA Ophthalmic Gel, an innovative treatment for moderate-to-severe dry eye disease (DED).
- Territorial Rights: PT. Erela will have exclusive rights to register, import, promote, distribute, market, and sell CsA Ophthalmic Gel across Indonesia.
- Financial Terms: Zhaoke will receive an upfront payment and is eligible for additional milestone payments based on specific achievements related to commercialization.
- Product Differentiation: CsA Ophthalmic Gel features a patented hydrogel with nanomicelle technology, offering enhanced corneal penetration and superior bioavailability compared with established treatments like Restasis®. Notably, it is administered once daily at night, which may lead to better patient compliance and convenience.
- Clinical Data: Phase II and III trials suggest the gel matches or exceeds the efficacy and safety of Restasis®, with a rapid onset of action in as little as two weeks.
- Partner Overview: PT. Erela is a well-established Indonesian pharmaceutical manufacturer with a diversified product portfolio and a distribution network reaching over 10,000 pharmacies and major hospitals nationwide.
- Strategic Importance: The partnership leverages PT. Erela’s strong regulatory and market capabilities to accelerate Zhaoke’s entry into the Indonesian and broader Southeast Asian pharmaceutical markets.
Details Investors Should Note
- Potential Revenue Impact: The upfront and milestone payments from PT. Erela could provide a significant boost to Zhaoke’s revenue streams, depending on the commercial success of CsA Ophthalmic Gel in Indonesia.
- Market Expansion: If successful, this deal could serve as a model for further regional expansion into other Southeast Asian countries, enhancing Zhaoke’s international growth prospects.
- Product Innovation: CsA Ophthalmic Gel’s unique formulation and once-daily dosing regimen could make it a preferred option over competitors, potentially driving strong market adoption.
- Risks and Uncertainties: A cautionary note to investors—the company cannot guarantee the ultimate development or commercial success of CsA Ophthalmic Gel in Indonesia, as regulatory and market risks remain.
- Share Price Sensitivity: The announcement of this exclusive deal and the potential new revenue streams may have a positive impact on Zhaoke’s share price. However, investors should be aware of the stated uncertainties regarding regulatory approval and market uptake.
About CsA Ophthalmic Gel
CsA Ophthalmic Gel is an innovative cyclosporine-based treatment for moderate-to-severe dry eye disease. Unlike Restasis® (an emulsion requiring twice-daily administration), this gel uses a patented hydrogel design with nanomicelle technology, offering enhanced mucoadhesion, corneal residence time, and improved drug bioavailability. Clinical trials indicate efficacy and safety profiles comparable or superior to Restasis®, with the added benefit of once-nightly dosing and a rapid onset of action within two weeks. This innovation aims to improve patient compliance and quality of life.
About PT. Erlangga Edi Laboratories (PT. Erela)
Founded in 1965, PT. Erela is among Indonesia’s leading pharmaceutical companies, with a product portfolio spanning over 150 SKUs, including pharmaceuticals, traditional medicines, health supplements, and beverages. PT. Erela serves both domestic and international markets and operates an extensive distribution network, reaching more than 10,000 pharmacy outlets and major hospital chains across the country. The company also offers professional toll manufacturing services and maintains strong regulatory compliance.
Board and Management
The Board of Zhaoke Ophthalmology comprises experienced professionals, including Dr. Li Xiaoyi (Chairman), Mr. Dai Xiangrong (Executive Director), as well as independent and non-executive directors with diverse expertise.
Important Caution
Disclaimer: This article contains forward-looking statements. Zhaoke Ophthalmology cannot guarantee the successful development or commercialization of CsA Ophthalmic Gel. Investors are advised to exercise caution and conduct their own due diligence when dealing in the shares of the Company.
【粵語版本】
兆科眼科與印尼PT. Erela簽訂CsA眼用凝膠獨家分銷協議
- 重大消息：兆科眼科有限公司（Zhaoke Ophthalmology）已與印尼知名藥企PT. Erlangga Edi Laboratories（PT. Erela）簽署獨家分銷及供應協議。
- 產品範疇：協議涵蓋CsA眼用凝膠，一種針對中重度乾眼症（DED）的創新藥物。
- 市場權益：PT. Erela獲得在印尼註冊、進口、推廣、分銷、營銷及銷售CsA眼用凝膠的獨家權利。
- 財務條款：兆科將獲得首付款及根據特定商業里程碑獲得額外付款。
- 產品創新：CsA眼用凝膠採用專利水凝膠及納米膠束技術，提升角膜穿透力及藥物生物可用性。相比競爭對手Restasis®，此產品僅需每日一次夜間用藥，患者依從性及便利性大幅提升。
- 臨床數據：II期及III期臨床試驗顯示，該藥效用及安全性與Restasis®持平或更佳，且最快兩星期即可見效。
- 合作夥伴簡介：PT. Erela是印尼領先藥企，擁有逾150種產品，分銷網絡覆蓋全國逾一萬家藥房及主要醫院。
- 戰略意義：此次合作將加快兆科進入印尼及東南亞醫藥市場的步伐，具備戰略擴張意義。
投資者須知重點
- 潛在收入影響：首付款及里程碑付款將為兆科帶來新收入來源，視乎產品商業推進情況，或對財務狀況帶來正面影響。
- 市場拓展空間：若合作順利，兆科或可複製模式，進一步拓展至東南亞其他市場，提升國際增長潛力。
- 產品競爭力：創新配方及每日一次用藥有望獲市場青睞，推動用戶採納。
- 風險提示：公司提醒，CsA眼用凝膠最終能否順利開發及商業化仍有不確定性，投資者須注意相關風險。
- 股價敏感事項：獨家分銷協議及潛在新增收入對股價或有正面影響，但亦需認清監管審批及市場反應等不確定因素。
產品及合作方簡介
CsA眼用凝膠： 以環孢素A為基礎、針對中重度乾眼症的創新療法，專利水凝膠配方配合納米膠束技術，提升角膜黏附力及生物可用性，每晚一次用藥，臨床數據支持其效能及安全性。
PT. Erela： 創立於1965年，現為印尼主要藥企之一，產品線包括藥品、保健品及飲品，分銷網絡廣泛，並提供藥品代工及專業技術服務。
董事會組成
兆科眼科董事會包括李小毅博士（主席）、戴翔榮先生（執行董事）及多位具專業背景的非執行及獨立董事。
重要聲明
免責聲明： 本文包含前瞻性陳述。兆科眼科不能保證CsA眼用凝膠最終能成功開發或商業化。投資者在買賣公司股份時應審慎行事，並自行進行風險評估。
